Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses Xenomics' US, European Patents for Prenatal Dx

NEW YORK (GenomeWeb News) – Sequenom said today that it has licensed from Xenomics intellectual property for use in prenatal research and diagnostic tests.
The exclusive license gives Sequenom global rights to use certain transrenal fetal nucleic acids in maternal urine for non-invasive prenatal diagnostics and analysis. The technology may be used on a technology-independent basis for “all uses,” excluding the determination of fetal gender solely by the presence of Y chromosome, Sequenom said.
The agreement, which covers the rights to US Patents 6,251,638 and RE 39,920 and European Patent EP 0920539, extends the company’s SEQureDx prenatal diagnostic technology by enabling it to develop products for noninvasive fetal sampling and testing.
Sequenom’s technology is based on other IP it licensed exclusively from Isis Innovation, the Chinese University of Hong Kong, and from Genomic Nanosystems.
Because the license rights are platform-independent, the company said, it may develop and commercialize tests on any platform, not limited to its MassArray system.
Financial terms of the agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.